摘要
激素抵抗性前列腺癌的治疗是目前前列腺癌治疗中的重点与难点。虽然各种治疗方法层出不穷,从化疗到放疗,从生物治疗到同位素治疗,但真正能延长生存的治疗方法并不多。多西他赛联合强的松方案已经成为治疗前列腺癌的一线化疗方案,可有效延长患者生存期。唑来膦酸能明显减少骨相关事件的发生率,已被广泛应用于前列腺癌骨转移的治疗。而生物靶向治疗在前列腺癌中的研究正热,已有许多初步有效的研究报道,进一步确切的疗效评估有待大样本研究证实。
Treatment of hormonal refractory prostate cancer （HRPC） is nowadays a challenge in the clinic. Although different types of treatment Such as chemotherapy, radiotherapy, biotherapy, and radioisotope treatment have been used, their effects on patients＇survival is uncertain. Docetaxel plus prednisone has been confirmed to be the first line regimen, which can effectively increase patients＇ survival. Zoladronic acid has been demonstrated to be efficacious in reducing bone related events, and has been widely applied in bone metastasis of prostate cancer. Targeted therapy is currently under intensive investigation for HRPC treatment, and many early clinical studies have shown their effective results, and further studies with larger samples may prove their efficacy. This review will cover different topics in terms of the treatment of hormonal refractory prostate cancer and update the progresses in recent clinical trials.
出处
《中国癌症杂志》
CAS
CSCD
2007年第3期220-224,共5页
China Oncology
关键词
激素抵抗
前列腺癌
化疗
生物治疗
hormone refractory
prostate cancer
chemotherapy
biotherapy
